BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Mar 06, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Zenapax daclizumab: Phase III; marketed to prevent renal transplant rejection

Researchers published in The New England Journal of Medicine results of a 55-patient independent study of Zenapax induction therapy to prevent cardiac transplant rejection. Acute rejection developed in 17...

Read the full 125 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >